Answers are grounded in this paper and cite their sources.
While novel antithrombotics like rivaroxaban and atopaxar show promise for ACS, their clinical implementation is currently limited by increased bleeding risks.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Amir Aziz (2013) conducted a review in Acute coronary syndromes. Novel oral anti-thrombotic drugs vs. Standard therapy or placebo was evaluated.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: